Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome

키워드

참고문헌 (140)

1. Longstreth GF, "Functional bowel disorders", Gastroenterology, 130, pp.1480~1491 (2006)
2. Longstreth GF, "Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective", Am J Gastroenterol, 98, pp.600~607 (2003)
3. Hungin AP, "Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact", Aliment Pharmacol Ther, 21, pp.1365~1375 (2005)
4. Grundmann O, "Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners", J Gastroenterol Hepatol, 25, pp.691~699 (2010)
5. El-Serag HB, "Health-related quality of life among persons with irritable bowel syndrome: a systematic review", Aliment Pharmacol Ther, 16, pp.1171~1185 (2002)
6. Gralnek IM, "The impact of irritable bowel syndrome on health-related quality of life", Gastroenterology, 119, pp.654~650 (2000)
7. Crowell MD, "New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments", Curr Gastroenterol Rep, 7, pp.272~279 (2005)
8. Hasler WL, "Traditional thoughts on the pathophysiology of irritable bowel syndrome", Gastroenterol Clin North Am, 40, pp.21~43 (2011)
9. Ohman L, "Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions", Nat Rev Gastroenterol Hepatol, 7, pp.163~173 (2010)
10. Pimentel M, "Inflammation and microflora", Gastroenterol Clin North Am, 40, pp.69~85 (2011)
11. Manabe N, "Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort", Neurogastroenterol Motil, 22, pp.293~e82 (2010)
12. Deiteren A, "Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome", Dig Dis Sci, 55, pp.384~391 (2010)
13. Oh Young Lee, "Asian Motility Studies in Irritable Bowel Syndrome", Journal of Neurogastroenterology and Motility (JNM), 16(2), pp.120~130 (2010), 대한소화기 기능성질환∙운동학회
14. Chey WY, "Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea", Am J Gastroenterol, 96, pp.1499~1506 (2001)
15. Ritchie J, "Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome", Gut, 14, pp.125~132 (1973)
16. Whitehead WE, "Tolerance for rectosigmoid distention in irritable bowel syndrome", Gastroenterology, 98(5 Pt 1), pp.1187~1192 (1990)
17. Mertz H, "Altered rectal perception is a biological marker of patients with irritable bowel syndrome", Gastroenterology, 109, pp.40~52 (1995)
18. Nozu T, "Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome", J Gastroenterol, 41, pp.217~222 (2006)
19. Spiller RC, "Potential biomarkers", Gastroenterol Clin North Am, 40, pp.121~139 (2011)
20. Zhou Q, "Central and peripheral hypersensitivity in the irritable bowel syndrome", Pain, 148, pp.454~461 (2010)
21. Tillisch K, "Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome", Gastroenterology, 140, pp.91~100 (2011)
22. Drossman DA, "Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome", Am J Med, 107(5A), pp.41S~50S (1999)
23. Ohman L, "New insights into the pathogenesis and pathophysiology of irritable bowel syndrome", Dig Liver Dis, 39, pp.201~215 (2007)
24. Garvin B, "The role of serotonin in irritable bowel syndrome: implications for management", Curr Gastroenterol Rep, 10, pp.363~368 (2008)
25. Houghton LA, "Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome", Gut, 52, pp.663~670 (2003)
26. Dunlop SP, "Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome", Clin Gastroenterol Hepatol, 3, pp.349~357 (2005)
27. Atkinson W, "Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome", Gastroenterology, 130, pp.34~43 (2006)
28. Thabane M, "Post-infectious irritable bowel syndrome", World J Gastroenterol, 15, pp.3591~3596 (2009)
29. Halvorson HA, "Postinfectious irritable bowel syndrome: a meta-analysis", Am J Gastroenterol, 101, pp.1894~1899 (2006)
30. Marshall JK, "Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen", Clin Gastroenterol Hepatol, 5, pp.457~460 (2007)
31. Soyturk M, "Irritable bowel syndrome in persons who acquired trichinellosis", Am J Gastroenterol, 102, pp.1064~1069 (2007)
32. Gonsalkorale WM, "Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component", Gut, 52, pp.91~93 (2003)
33. van der Veek PP, "Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome", Am J Gastroenterol, 100, pp.2510~2516 (2005)
34. Lin HC, "Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome", JAMA, 292, pp.852~858 (2004)
35. Ford AC, "Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis", Clin Gastroenterol Hepatol, 7, pp.1279~1286 (2009)
36. Malinen E, "Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR", Am J Gastroenterol, 100, pp.373~382 (2005)
37. Kassinen A, "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects", Gastroenterology, 133, pp.24~33 (2007)
38. Carroll IM, "Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome", Gut Pathog, 2(19) (2010)
39. Kerckhoffs AP, "Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome", J Med Microbiol, 60(Pt 2), pp.236~245 (2011)
40. Park MI, "Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment", Gastroenterol Clin North Am, 34, pp.305~317 (2005)
41. Nastaskin I, "Studying the overlap between IBS and GERD: a systematic review of the literature", Dig Dis Sci, 51, pp.2213~2120 (2006)
42. Ford AC, "Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia", Clin Gastroenterol Hepatol, 8, pp.401~409 (2010)
43. Lee SY, "Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study", Digestion, 79, pp.196~201 (2009)
44. Kaji M, "Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life", J Gastroenterol Hepatol, 25, pp.1151~1156 (2010)
45. De Vries DR, "Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease", Scand J Gastroenterol, 42, pp.951~956 (2007)
46. Nojkov B, "The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 27, pp.473~482 (2008)
47. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, "An evidence-based position statement on the management of irritable bowel syndrome", Am J Gastroenterol, 104(Suppl 1), pp.S1~S35 (2009)
48. Stevens J, "Comparison of the effects of psyllium and wheat bran on gastrointestinal transit time and stool characteristics", J Am Diet Assoc, 88, pp.323~326 (1988)
49. Bijkerk CJ, "Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial", BMJ, 339, pp.b3154~ (2009)
50. Khoshoo V, "Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome", Aliment Pharmacol Ther, 23, pp.191~196 (2006)
51. Gershon MD, "The serotonin signaling system: from basic understanding to drug development for functional GI disorders", Gastroenterology, 132, pp.397~414 (2007)
52. Degen L, "Effect of tegaserod on gut transit in male and female subjects", Neurogastroenterol Motil, 17, pp.821~826 (2005)
53. Müller-Lissner SA, "Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation", Aliment Pharmacol Ther, 15, pp.1655~1666 (2001)
54. Novick J, "A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation", Aliment Pharmacol Ther, 16, pp.1877~1888 (2002)
55. Lefkowitz M, "Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS", Gut, 47(Suppl 3), pp.A217~ (2000)
56. Chey WD, "Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial", Am J Gastroenterol, 103, pp.1217~1225 (2008)
57. Kellow J, "An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome", Gut, 52, pp.671~676 (2003)
58. Nyhlin H, "A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome", Scand J Gastroenterol, 39, pp.119~126 (2004)
59. Tougas G, "Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome", Aliment Pharmacol Ther, 16, pp.1701~1708 (2002)
60. Thompson CA, "Novartis suspends tegaserod sales at FDA’s request", Am J Health Syst Pharm, 64, pp.1020~ (2007)
61. Serebruany VL, "Investigations on 5-HT4 receptor expression and effects of tegaserod on human platelet aggregation in vitro", Am J Ther, 17, pp.543~552 (2010)
62. Schoenfeld P, "Review article: the safety profile of tegaserod", Aliment Pharmacol Ther, 20(Suppl 7), pp.25~30 (2004)
63. Maneerattanaporn M, "Emerging pharmacological therapies for the irritable bowel syndrome", Gastroenterol Clin North Am, 40, pp.223~243 (2011)
64. Johanson JF, "Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation", Aliment Pharmacol Ther, 27, pp.685~696 (2008)
65. Drossman DA, "Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies", Aliment Pharmacol Ther, 29, pp.329~341 (2009)
66. Lembo AJ, "Efficacy of linaclotide for patients with chronic constipation", Gastroenterology, 138, pp.886~895 (2010)
67. Lembo A, "286 efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials", Gastroenterology, 138(5 Suppl 1), pp.S53~S54 (2010)
68. ".Available from"[URL]
69. Shailubhai K, "Phase II clinical evaluation of SP-304, a guanylate cyclase-C agonist, for treatment of chronic constipation", Am J Gastroenterol, 105, pp.S487~S488 (2010)
70. Rao AS, "Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis", Gastroenterology, 139, pp.1549~1558 (2010)
71. Chey WD, "A3309, an ileal bile acid transport (IBAT", ASBT) inhibitor, significantly improved stool frequency and other constipation-related complaints in adults with chronic constipation: data from an 8-week, randomized, double-blind, placebo-controlled study, 2011, pp.140(5 Suppl 1), S3~
72. Cann PA, "Role of loperamide and placebo in management of irritable bowel syndrome (IBS)", Dig Dis Sci, 29, pp.239~247 (1984)
73. Hovdenak N, "Loperamide treatment of the irritable bowel syndrome", Scand J Gastroenterol Suppl, 130, pp.81~84 (1987)
74. Lavö B, "Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study", Scand J Gastroenterol Suppl, 130, pp.77~80 (1987)
75. Efskind PS, "A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome", Scand J Gastroenterol, 31, pp.463~468 (1996)
76. Talley NJ, "GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man", Dig Dis Sci, 35, pp.477~480 (1990)
77. Zighelboim J, "Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism", Dig Dis Sci, 40, pp.819~827 (1995)
78. Delvaux M, "Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome", Aliment Pharmacol Ther, 12, pp.849~855 (1998)
79. Houghton LA, "Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers", Aliment Pharmacol Ther, 14, pp.775~782 (2000)
80. Camilleri M, "Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial", Lancet, 355, pp.1035~1040 (2000)
81. Camilleri M, "A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome", Arch Intern Med, 161, pp.1733~1740 (2001)
82. Watson ME, "Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome", Am J Gastroenterol, 96, pp.455~459 (2001)
83. Lembo T, "Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome", Am J Gastroenterol, 96, pp.2662~2670 (2001)
84. Chey WD, "Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome", Am J Gastroenterol, 99, pp.2105~2203 (2004)
85. Chang L, "A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS", Am J Gastroenterol, 100, pp.115~123 (2005)
86. Chang L, "Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data", Am J Gastroenterol, 101, pp.1069~1079 (2006)
87. Ford AC, "Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis", Am J Gastroenterol, 104, pp.1831~1843 (2009)
88. Matsueda K, "A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome", Digestion, 77, pp.225~235 (2008)
89. Frissora CL, "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome", Aliment Pharmacol Ther, 25, pp.1271~1281 (2007)
90. Lembo A, "T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response", Gastroenterology, 134(4 Suppl 1), pp.A545~ (2008)
91. Pimentel M, "Rifaximin therapy for patients with irritable bowel syndrome without constipation", N Engl J Med, 364, pp.22~32 (2011)
92. Pimentel M, "The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial", Ann Intern Med, 145, pp.557~563 (2006)
93. Tack J, "Antibiotic therapy for the irritable bowel syndrome", N Engl J Med, 364, pp.81~82 (2011)
94. Lauritano EC, "Small intestinal bacterial overgrowth recurrence after antibiotic therapy", Am J Gastroenterol, 103, pp.2031~2035 (2008)
95. Camilleri M, "Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation.", Neurogastroenterol Motil, 29, pp.971~979 (2008)
96. Mangel AW, "Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome", Aliment Pharmacol Ther, 28, pp.239~249 (2008)
97. Tack JF, "S1298 AST-120 (spherical carbon adsorbent) improves pain and bloating in a randomized, double-blind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS).", Gastroenterology, 138(5 Suppl 1), pp.S223~ (2010)
98. Sweetser S, "Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome", Am J Physiol Gastrointest Liver Physiol, 296, pp.G1299~G1306 (2009)
99. Dukes GE, "A randomised, double blind, placebo controlled, crossover study to evaluate the efficacy and safety of the CRF1 receptor antagonist GW876008 in irritable bowel syndrome patients", Neurogastroenterol Motil, 21, pp.84~ (2009)
100. Mangel AW, "Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients", Digestion, 78, pp.180~186 (2008)
101. Leventer SM, "Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome", Aliment Pharmacol Ther, 27, pp.197~206 (2008)
102. Brown P, "907 LX1031, a novel locally-acting inhibitor of serotonin (5-HT) synthesis significantly improves symptoms in patients with IBS", Gastroenterology, 138(5 Suppl 1), pp.S129~ (2010)
103. Talley NJ, "Pharmacologic therapy for the irritable bowel syndrome", Am J Gastroenterol, 98, pp.750~758 (2003)
104. Darvish-Damavandi M, "A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome", World J Gastroenterol, 16, pp.547~553 (2010)
105. Poynard T, "Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome", Aliment Pharmacol Ther, 15, pp.355~361 (2001)
106. Jailwala J, "Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials", Ann Intern Med, 133, pp.136~147 (2000)
107. Goulding MR, "Inappropriate medication prescribing for elderly ambulatory care patients", Arch Intern Med, 164, pp.305~312 (2004)
108. Ford AC, "Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis", Gut, 58, pp.367~378 (2009)
109. Lesbros-Pantoflickova D, "Meta-analysis: the treatment of irritable bowel syndrome", Aliment Pharmacol Ther, 20, pp.1253~1269 (2004)
110. Gorard DA, "Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome", Aliment Pharmacol Ther, 8, pp.159~166 (1994)
111. Brennan BP, "Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study", Hum Psychopharmacol, 24, pp.423~428 (2009)
112. Chial HJ, "Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans", Clin Gastroenterol Hepatol, 1, pp.211~218 (2003)
113. Kong SC, "The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases", J Clin Gastroenterol, 39, pp.138~141 (2005)
114. van Tilburg MA, "Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO", BMC Complement Altern Med, 8, pp.46~ (2008)
115. Borowiec AM, "The role of probiotics in management of irritable bowel syndrome", Curr Gastroenterol Rep, 9, pp.393~400 (2007)
116. Moayyedi P, "The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review", Gut, 59, pp.325~332 (2010)
117. Brenner DM, "The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review", Am J Gastroenterol, 104, pp.1033~1049 (2009)
118. O’Mahony L, "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles", Gastroenterology, 128, pp.541~551 (2005)
119. Whorwell PJ, "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome", Am J Gastroenterol, 101, pp.1581~1590 (2006)
120. Bian Z, "Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review", J Altern Complement Med, 12, pp.401~407 (2006)
121. Hills JM, "The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig.", Gastroenterology, 101, pp.55~65 (1991)
122. Hawthorn M, "The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations", Aliment Pharmacol Ther, 2, pp.101~118 (1988)
123. Pittler MH, "Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis", Am J Gastroenterol, 93, pp.1131~1135 (1998)
124. Spanier JA, "A systematic review of alternative therapies in the irritable bowel syndrome", Arch Intern Med, 163, pp.265~274 (2003)
125. Ford AC, "Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis", BMJ, 337, pp.a2313~ (2008)
126. Merat S, "The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome", Dig Dis Sci, 55, pp.1385~1390 (2010)
127. Bensoussan A, "Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial", JAMA, 280, pp.1585~1589 (1998)
128. Liu JP, "Herbal medicines for treatment of irritable bowel syndrome", Cochrane Database Syst Rev, (1), pp.CD004116~ (2006)
129. Saito YA, "A randomized, double-blind, placebo-controlled trial of St John’s wort for treating irritable bowel syndrome", Am J Gastroenterol, 105, pp.170~177 (2010)
130. Fireman Z, "Acupuncture treatment for irritable bowel syndrome: a double-blind controlled study", Digestion, 64, pp.100~103 (2001)
131. Forbes A, "Acupuncture for irritable bowel syndrome: a blinded placebo-controlled trial", World J Gastroenterol, 11, pp.4040~4044 (2005)
132. Schneider A, "Acupuncture treatment in irritable bowel syndrome", Gut, 55, pp.649~654 (2006)
133. Lembo AJ, "A treatment trial of acupuncture in IBS patients", Am J Gastroenterol, 104, pp.1489~1497 (2009)
134. Saito YA, "The epidemiology of irritable bowel syndrome in North America: a systematic review", Am J Gastroenterol, 97, pp.1910~1915 (2002)
135. Talley NJ, "Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization", Am J Epidemiol, 142, pp.76~83 (1995)
136. Talley NJ, "Epidemiology of colonic symptoms and the irritable bowel syndrome", Gastroenterology, 101, pp.927~934
137. Guilera M, "Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review", Am J Gastroenterol, 100, pp.1174~1184 (2005)
138. "Systematic review on the management of irritable bowel syndrome in the European Union", Eur J Gastroenterol Hepatol, 19(Suppl 1), pp.S11~S37 (2007)
139. Gwee KA, "Asian consensus on irritable bowel syndrome", J Gastroenterol Hepatol, 25, pp.1189~1205 (2010)
140. Gwee KA, "Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed", J Gastroenterol Hepatol, 24, pp.1601~1607 (2009)

관련 논문AI추천